Literature DB >> 8633000

Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen.

M J McElrath1, L Corey, P D Greenberg, T J Matthews, D C Montefiori, L Rowen, L Hood, J I Mullins.   

Abstract

With efforts underway to develop a preventive human immunodeficiency virus type 1 (HIV-1) vaccine, it remains unclear which immune responses are sufficient to protect against infection and whether prior HIV-1 immunity can alter the subsequent course of HIV-1 infection. We investigated these issues in the context of a volunteer who received six HIV-1LAI envelope immunizations and 10 weeks thereafter acquired HIV-1 infection through a high-risk sexual exposure. In contrast to nonvaccinated acutely infected individuals, anamnestic HIV-1-specific B- and T-cell responses appeared within 3 weeks in this individual, and neutralizing antibody preceded CD8+ cytotoxic responses. Despite an asymptomatic course and an initial low level of detectable infectious virus, a progressive CD4+ cell decline and dysfunction occurred within 2 years. Although vaccination elicited immunity to HIV-1 envelope, which was recalled upon HIV-1 exposure, it was insufficient to prevent infection and subsequent immunodeficiency.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8633000      PMCID: PMC39470          DOI: 10.1073/pnas.93.9.3972

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. Multicenter AIDS Cohort Study Group.

Authors:  D C Montefiori; L B Lefkowitz; R E Keller; V Holmberg; E Sandstrom; J P Phair
Journal:  AIDS       Date:  1991-05       Impact factor: 4.177

2.  Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein.

Authors:  E L Cooney; A C Collier; P D Greenberg; R W Coombs; J Zarling; D E Arditti; M C Hoffman; S L Hu; L Corey
Journal:  Lancet       Date:  1991-03-09       Impact factor: 79.321

3.  Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV.

Authors:  M L Marthas; S Sutjipto; J Higgins; B Lohman; J Torten; P A Luciw; P A Marx; N C Pedersen
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

4.  Plasma viremia in human immunodeficiency virus infection.

Authors:  R W Coombs; A C Collier; J P Allain; B Nikora; M Leuther; G F Gjerset; L Corey
Journal:  N Engl J Med       Date:  1989-12-14       Impact factor: 91.245

5.  HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay.

Authors:  M Koot; A H Vos; R P Keet; R E de Goede; M W Dercksen; F G Terpstra; R A Coutinho; F Miedema; M Tersmette
Journal:  AIDS       Date:  1992-01       Impact factor: 4.177

6.  Initial low CD4 lymphocyte counts in recent human immunodeficiency virus infection and lack of association with identified coinfections.

Authors:  P J Weiss; S K Brodine; R R Goforth; C A Kennedy; M R Wallace; P E Olson; F C Garland; F W Hall; S I Ito; E C Oldfield
Journal:  J Infect Dis       Date:  1992-11       Impact factor: 5.226

7.  Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism.

Authors:  B Chesebro; K Wehrly; J Nishio; S Perryman
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

8.  Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

Authors:  S L Hu; K Abrams; G N Barber; P Moran; J M Zarling; A J Langlois; L Kuller; W R Morton; R E Benveniste
Journal:  Science       Date:  1992-01-24       Impact factor: 47.728

9.  The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.

Authors:  R Dolin; B S Graham; S B Greenberg; C O Tacket; R B Belshe; K Midthun; M L Clements; G J Gorse; B W Horgan; R L Atmar
Journal:  Ann Intern Med       Date:  1991-01-15       Impact factor: 25.391

10.  Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion.

Authors:  J W Mellors; L A Kingsley; C R Rinaldo; J A Todd; B S Hoo; R P Kokka; P Gupta
Journal:  Ann Intern Med       Date:  1995-04-15       Impact factor: 25.391

View more
  10 in total

1.  Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection.

Authors:  Helen Horton; Colin Havenar-Daughton; Deborah Lee; Erin Moore; Jianhong Cao; John McNevin; Thomas Andrus; Haiying Zhu; Abbe Rubin; Tuofu Zhu; Connie Celum; M Juliana McElrath
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Matrix-assisted laser desorption ionization/mass spectrometry mapping of human immunodeficiency virus-gp120 epitopes recognized by a limited polyclonal antibody.

Authors:  S Jeyarajah; C E Parker; M T Summer; K B Tomer
Journal:  J Am Soc Mass Spectrom       Date:  1998-02       Impact factor: 3.109

3.  Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope.

Authors:  J Richardson; A Moraillon; S Baud; A M Cuisinier; P Sonigo; G Pancino
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

4.  Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.

Authors:  T C VanCott; J R Mascola; L D Loomis-Price; F Sinangil; N Zitomersky; J McNeil; M L Robb; D L Birx; S Barnett
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

5.  Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.

Authors:  R I Connor; B T Korber; B S Graham; B H Hahn; D D Ho; B D Walker; A U Neumann; S H Vermund; J Mestecky; S Jackson; E Fenamore; Y Cao; F Gao; S Kalams; K J Kunstman; D McDonald; N McWilliams; A Trkola; J P Moore; S M Wolinsky
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

6.  The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.

Authors:  Abraham Pinter; William J Honnen; Yuxian He; Miroslaw K Gorny; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  Evidence for lack of cross-genotype protection of CD4+ T cell responses during chronic hepatitis C virus infection.

Authors:  G C Harcourt; M Lucas; A J Godkin; M Kantzanou; R E Phillips; P Klenerman
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

8.  Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen.

Authors:  Robert H Mealey; Steven R Leib; Matt H Littke; Bettina Wagner; David W Horohov; Travis C McGuire
Journal:  Vaccine       Date:  2009-02-24       Impact factor: 3.641

Review 9.  Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS.

Authors:  Satish Kumar Gupta
Journal:  HIV AIDS (Auckl)       Date:  2013-10-22

Review 10.  CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations - a review, hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.198

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.